Articles

admin

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

2024-03-27 Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer(Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer) Strong…

View details
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference

2024-03-07 CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference   Drug Combination’s Unique Mechanism of Action Enables Reactivation of Brain Adrenergic Function, Showing Improvements in Multiple Areas of Cognition San Carlos, CA and Lisbon, Portugal, March 7, 2024 –…

View details
Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU

2024-05-31 Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU Despite CHMP upholding the negative opinion for treatment of cerebral  adrenoleukodystrophy (cALD) the companies remain committed to the continued development of NEZGLYAL® for cALD Barcelona, Spain and Düsseldorf, Germany – 31 May, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies…

View details
Aura Biosciences to Participate in Upcoming Investor Conferences

2024-05-8 Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, May 08, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:…

View details
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

2024-05-09 Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE)…

View details
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

2024-05-23 Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024 BOSTON, May 23, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will…

View details
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

2024-05-30 Aura Biosciences to Participate in the Jefferies Global Healthcare Conference     BOSTON, May 30, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies…

View details
Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy – special film launched

2024-02-29 Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy – special film launched Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Minoryx Therapeutics, a late stage biotech…

View details
Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences to Participate in Upcoming Investor ConferencesFebruary 26, 2024PDF Version BOSTON–(BUSINESS WIRE)–Feb. 26, 2024– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: 44th Annual TD…

View details
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

December 14, 2023 The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic…

View details